Compare Mesoblast Limited (MESO) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Raytheon Technologies Corp — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Raytheon Technologies Corp trades at $184.94 (market cap $242.95B). The key difference: Raytheon Technologies Corp is far larger — about 134.2× Mesoblast Limited's market cap, and Raytheon Technologies Corp pays a 1.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Raytheon Technologies Corp for 78 Days on average.
| MESO | RTX | |
|---|---|---|
Market Cap | $1.81B | $242.95B |
Volume | 240,620 | 4,213,378 |
Sector | Health | Industrials |
52-Week High | $20.96 | $225.49 |
52-Week Low | $13.19 | $157.00 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | $1.89B | $273.50B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
RTX trades at $184.32, up 0.56% today, with strong fundamental momentum as revenue grew to $88.6B in 2025 and net income reached $6.73B. The company has beaten earnings estimates for three consecutive quarters, supported by a massive $289B backlog. Technical indicators show a bearish short-term trend despite bullish oscillators, while analyst consensus remains strongly positive with a $237.60 price target.
RTX presents a compelling investment case with robust defense sector tailwinds and consistent earnings outperformance. Key risks include execution challenges in managing the large backlog and potential defense budget volatility. The stock offers 29% upside to consensus targets, making it attractive for long-term investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
